Bicyclo Patents (Class 514/681)
  • Patent number: 9687456
    Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, a nutritional composition includes exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: June 27, 2017
    Assignee: Nestec S.A.
    Inventors: Douglas Richard Bolster, Zamzam Kabiry Roughead
  • Patent number: 9579355
    Abstract: The present invention is a composition and method of treatment for actinic purpura, skin disorders, and skin conditions in general through topical systematic and periodic application of a formulation that generally may include ingredients to improve circulation such as but not limited to arnica oil CLR and phytotonine; ingredients to thicken the skin such as but not limited to retistar, glycolic acid, vitamin K1, and phyto-age; and ingredients to repair the skin's barrier, such as but not limited to timecode, SKINMIMICS, ABS pomegranate sterols, and pentatavitin.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 28, 2017
    Assignee: Clark Pharmaceuticals LLC
    Inventors: Stephen W. Clark, Natalie Barger
  • Publication number: 20150148362
    Abstract: The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Won Ki Kim, Yongseok Choi, Sumi Song
  • Publication number: 20150141521
    Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Inventors: Stanley J. Watowich, Usha Viswanathan
  • Publication number: 20150141339
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Application
    Filed: October 21, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Hodges, Robin Soper
  • Publication number: 20150133564
    Abstract: Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.
    Type: Application
    Filed: April 2, 2014
    Publication date: May 14, 2015
    Applicants: SNU R&DB FOUNDATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dong-Chan OH, Seong-Hwan KIM, Jongheon SHIN, Hak Cheol KWON, So Hee KWON
  • Publication number: 20150126454
    Abstract: A composition that is useful in a skin function improving agent includes at least two of the following: vitamin K, a sapogenol, and a collagen hydrolysate. This composition can be used in a skin function improving agent and is particularly useful in a skin function improving agent for inhibiting transdermal moisture loss and/or for retaining the moisture in the stratum corneum.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Shuichi KAMO, Toshiro SATO, Rumi KAWAHARA, Shunsuke SUZUKI
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Publication number: 20150072980
    Abstract: The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor ?t (ROR?t)/ROR?. The compounds of the present invention are useful for modulating ROR?t)/ROR? activity and for treating diseases or conditions mediated by ROR?t)/ROR? such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 12, 2015
    Inventors: Hariprasad Vankayalapati, Venkatakrishnareddy Yerramreddy
  • Publication number: 20150051293
    Abstract: An object of the present invention is to provide a therapeutic preparation and method for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning. The present invention provides a therapeutic preparation comprising a pterosin derivative or a pharmaceutically acceptable salt thereof for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning; and a therapeutic method for the diseases.
    Type: Application
    Filed: October 14, 2014
    Publication date: February 19, 2015
    Inventors: Noriyuki TSUMAKI, Hiroshi TAKEMORI, Hiroyuki FUCHINO, Nobuo KAWAHARA
  • Publication number: 20150025155
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 22, 2015
    Inventors: Hongxi XU, Xin LI, Hong ZHANG, Yuanzhi LAO, Hongsheng TAN, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150018355
    Abstract: Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 15, 2015
    Inventors: Mark R. Kelley, Melissa L. Fishel, Angelo A. Cardoso
  • Publication number: 20150011646
    Abstract: This invention is related to compounds isolated from various Garcinia species and method of treating cancer. The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer.
    Type: Application
    Filed: January 8, 2014
    Publication date: January 8, 2015
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Yuanzhi LAO, Zhichao XI, Hongsheng TAN, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140314867
    Abstract: A vitamin K2 microsphere. The microsphere includes a poly(lactide-co-glycolide) acid (PLGA) particle, in which the Mw of PLGA is between 1000 and 300000, and the molar ratio between the lactide repeat units and the glycolide repeate unit is 1-9:9-1; and one or more vitamin K2 molecules are embedded in the PLGA particle, wherein the vitamin K2 is present in an amount of 0.005-75 wt %, based on the weight of the microsphere. Also disclosed are a method of preparing the vitamin K2 microsphere, a method of treating osteoporosis using this microsphere, and a pharmaceutical composition containing the microsphere.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicant: Medical and Pharmaceutical Industry Technology and Development Center
    Inventors: Shu-Wen Whu, Chung-Chih Cheng, Chih-Chiang Yang
  • Publication number: 20140309186
    Abstract: A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Jeffrey Skolnick, Adrian K. Arakaki, John McDonald, Roman Mezencev, Nathan Bowen
  • Publication number: 20140303119
    Abstract: The present invention teaches a method and new use for anticoagulant compounds for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) and other conditions. CRVO and BRVO represent debilitating conditions for which there is currently no effective therapy. The present invention teaches a new therapy, including new uses for existing pharmacological agents, comprising enoxaparin sodium, warfarin, clopidrogel, and others, in the treatment of these and other conditions.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 9, 2014
    Applicant: DiLorenzo Biomedical, LLC
    Inventor: Daniel John DiLorenzo
  • Publication number: 20140294860
    Abstract: The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 2, 2014
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Michael Platten, Christiane Opitz, Wolfgang Wick, Ulricke Litzenburger
  • Publication number: 20140243404
    Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.
    Type: Application
    Filed: September 13, 2011
    Publication date: August 28, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
  • Publication number: 20140242179
    Abstract: The present patent application relates to a novel coating system, coated compositions with such a coating system, as well as to the use of such compositions in the production food, feed, dietary supplements and/or pharmaceutical products, as well as to food, feed, dietary supplements and/or pharmaceutical products comprising such compositions.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 28, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Sylvain Diguet, Bruno H. Leuenberger, Fabien Laboulfie, Mehrdji Hemati
  • Patent number: 8815953
    Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: August 26, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Christopher G. Salentine, Kieran O'Donoghue
  • Publication number: 20140235619
    Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.
    Type: Application
    Filed: November 26, 2013
    Publication date: August 21, 2014
    Applicant: NONO INC.
    Inventors: Xiujun Sun, Michael Tymianski, David Garman
  • Publication number: 20140228447
    Abstract: Provided is a substance which is a safer and more commonly-consumed food ingredient that increase the testosterone level. The testosterone enhancer of the invention comprises vitamin K as an active ingredient. The vitamin is preferably menaquinone-4 and/or menaquinone-7. This enhancer is useful as pharmaceutical agents, supplements, health foods or functional foods for the prevention, amelioration and/or treatment of a condition or disease induced by the decreased testosterone level.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicants: Tohoku University, J. Oil Mills
    Inventors: Michio Komai, Hitoshi Shirakawa, Yusuke Ohsaki, Tadashi Takumi, Asagi Ito, Toshiro Sato, Rumi Ozaki
  • Publication number: 20140194530
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Yuanzhi Lao, Hongsheng Tan, Naihan Xu, Xiaoyu Wang, Zhenyan Liu, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20140194529
    Abstract: This invention relates to the use of a compound from natural sources for therapeutic uses. More particularly, it relates to a compound, Garcimultiflorone E, naturally occurring in the plant of Garcinia esculenta Y. H. Li which has potent anti-inflammation and anti-cancer effect.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Dandan ZHANG, Hong ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194499
    Abstract: Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones A and C, are disclosed in the present invention. Garciesculentones A and C exhibit cytotoxicity and/or antimigration effect against various cancer cell lines. The experimental results of the present invention suggest that Garciesculentones A and C are useful for developing into anticancer drugs.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Dandan ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140128257
    Abstract: Provided are pesticidal compositions comprising 4,5-dihydroxyindan-1-one or derivatives thereof for protecting important crops against mites, fungi, and bacteria. The compositions may be manufactured by fractionating fungal extracts.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 8, 2014
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREBREW UNINVERSITY OF JERUSALM LT
    Inventors: Abraham Sztejnberg, Uri Gerson, Zahi Paz, Zohar Kerem, Izhak Bilkis
  • Publication number: 20140121187
    Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.
    Type: Application
    Filed: June 18, 2012
    Publication date: May 1, 2014
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Young Sik Jung, Chong Kgo Lee, Ihl Young Choi, Hae Soo Kim, Pil Ho Kim, Soo Bong Han, Johan Neyts, Hendrik Jan Thibaut
  • Patent number: 8686049
    Abstract: Provided is a substance which is a safer and more commonly-consumed food ingredient that increase the testosterone level. The testosterone enhancer of the invention comprises vitamin K as an active ingredient. The vitamin is preferably menaquinone-4 and/or menaquinone-7. This enhancer is useful as pharmaceutical agents, supplements, health foods or functional foods for the prevention, amelioration and/or treatment of a condition or disease induced by the decreased testosterone level.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: April 1, 2014
    Assignees: Tohoku University
    Inventors: Michio Komai, Hitoshi Shirakawa, Yusuke Ohsaki, Tadashi Takumi, Asagi Ito, Toshiro Sato, Rumi Ozaki
  • Publication number: 20140088185
    Abstract: A buccally administered dosage for assisting with the relief of common digestive complaints where the dosage formed into a hard candy dosage drop, where the dosage is a sugar base infused with a botanical derivative that has concentrated active compositions in sufficient concentration to provide a soothing effect of digestive upset, and where the drop has favorable organoleptic properties.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Inventors: Dustin Garth James, Helen Kim-James
  • Publication number: 20140031432
    Abstract: Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with vitamin K are disclosed.
    Type: Application
    Filed: August 4, 2011
    Publication date: January 30, 2014
    Applicant: Ampere Life Sciences, Inc.
    Inventors: Orion D. Jankowski, Andrew W. Hinman, Guy M. Miller
  • Publication number: 20140030224
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 30, 2014
    Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • Patent number: 8633242
    Abstract: The present invention relates to benzylidene indanones of general formula 1. The compounds exhibited tubulin polymerisation inhibition. A series of compounds 2-benzylidene 3-(3,4,5-trimethoxyphenyl) indanones having general formula 1 were synthesized from gallic acid through a chemical process. 2-(3,4-Methylenedioxybenzylidine), 3-(3,4,5-trimethoxyphenyl), 4,5,6-trimethoxyindanone (8), a representative compound of this series possessing the molecular formula C29H28O9, was synthesized from gallic acid and exhibits potent anticancer activity. Compound 8 was evaluated for acute oral activity in Swiss albino mice and found to be safe up to 300 mg/kg body weight. The anticancer activity of the compounds has been determined, in order to obtain new potent and cost effective molecules using an in vitro cytotoxicity assay.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: January 21, 2014
    Assignee: Council of Scientific and Industrial Research
    Inventors: Arvind Singh Negi, Ayyampudur Palanisamy Prakasham, Ajit Kumar Saxena, Suaib Luqman, Debabrata Chanda, Tandeep Kaur, Atul Gupta
  • Publication number: 20130345223
    Abstract: The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. The present invention is further directed to in vitro- and in vzivo-based methods of inhibiting Lpd and/or PDH activity. In certain embodiments, these methods are useful in inhibiting Lpd and/or PDH activity key to a pathogen's survival.
    Type: Application
    Filed: June 28, 2011
    Publication date: December 26, 2013
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Ying-Ta Wu
  • Patent number: 8603947
    Abstract: A description is given of (4-haloalkyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, Y, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: December 10, 2013
    Assignee: Bayer Cropscience AG
    Inventors: Hartmut Ahrens, Dieter Feucht, Elmar Gatzweiler, Isolde Haeuser-Hahn, Christopher Hugh Rosinger
  • Publication number: 20130316906
    Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, R4, R5, Y, Q and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as herbicides and/or pesticides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as pesticides and/or for preventing unwanted plant growth.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Alfred Angermann, Stefan Lehr, Guido Bojack, Reiner Fischer, Isolde Häuser-hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Arnd Voerste, Dieter Feucht
  • Publication number: 20130281389
    Abstract: Topoisomerase II alpha (topo II?) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo II? is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo II? to the export receptor CRM1. Inhibition was specific to topo II? as p53 trafficking was unaffected along with topo II? protein expression and function (decatenation). These topo II?-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 24, 2013
    Inventors: Daniel M. Sullivan, Thomas C. Rowe, David A. Ostrov, Joel G. Turner
  • Publication number: 20130281544
    Abstract: The present invention discloses the hepatoprotective potential of garcinol.
    Type: Application
    Filed: December 29, 2011
    Publication date: October 24, 2013
    Inventors: Muhammed Majeed, Sarang Bani
  • Publication number: 20130267606
    Abstract: Vitamin K is effective in counteracting (1) increase of body weight and body mass index (BMI), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 10, 2013
    Applicant: VITAK B.V.
    Inventor: Cees Vermeer
  • Publication number: 20130237613
    Abstract: The present invention relates to a thermodynamically stable, biocompatible, environment friendly, and temperature-insensitive microemulsion containing various botanical essential oils, sugar based surfactants, polyhydric alcohols, and an aqueous phase.
    Type: Application
    Filed: September 4, 2012
    Publication date: September 12, 2013
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sanggu Kim
  • Publication number: 20130224286
    Abstract: Human viral infections can cause lesions of the skin and/or mucous membranes. Provided herein are 1,4-naphthoquinone family compounds which are useful in the treatment of these lesions. Further provided herein are pharmaceutical compositions comprising a 1,4-naphthoquinone family compound and methods of using such compositions in the treatment of these lesions.
    Type: Application
    Filed: October 20, 2011
    Publication date: August 29, 2013
    Inventor: Ambros Hügin
  • Publication number: 20130225517
    Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: University of Iowa Research Foundation
    Inventor: University of Iowa Research Foundation
  • Patent number: 8507555
    Abstract: Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC2”) and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in a subject in need of such treatment.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: August 13, 2013
    Assignee: Summa Health System
    Inventors: Thomas M. Miller, James M. Jamison
  • Publication number: 20130189316
    Abstract: In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP.
    Type: Application
    Filed: November 28, 2012
    Publication date: July 25, 2013
    Applicant: Latitude Pharmaceuticals Inc.
    Inventor: Latitude Pharmaceuticals Inc.
  • Publication number: 20130158037
    Abstract: The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. The present invention is further directed to in vitro- and in vzivo-based methods of inhibiting Lpd and/or PDH activity. In certain embodiments, these methods are useful in inhibiting Lpd and/or PDH activity key to a pathogen's survival.
    Type: Application
    Filed: June 28, 2011
    Publication date: June 20, 2013
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Ying-Ta Wu
  • Publication number: 20130137640
    Abstract: A composition includes a food ingredient or nutrient with safety and experience having been eaten for a long time and that shows a collagen enhancing activity. The food ingredient or nutrient of the composition includes a skin collagen enhancing agent that includes menaquinone-7 as an active ingredient. The composition including skin collagen enhancing agent can be administered percutaneously or orally as a drug, a cosmetic, or a supplement.
    Type: Application
    Filed: October 3, 2012
    Publication date: May 30, 2013
    Applicant: J-OIL MILLS, INC.
    Inventor: J-OIL MILLS, INC.
  • Publication number: 20130123367
    Abstract: The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders.
    Type: Application
    Filed: July 27, 2011
    Publication date: May 16, 2013
    Applicant: MEDIZINISCHE UNIVERSITAT WIEN
    Inventors: Thomas Erker, Gerda Brunhofer, Ulrich Jäger, Katrina Vanura, Verena Dirsch, Elke Heiss
  • Patent number: 8435497
    Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 7, 2013
    Assignee: Takeda GmbH
    Inventors: Klaus Dietzel, Helgert Mueller
  • Publication number: 20130102650
    Abstract: The present invention relates to a compound having formula (I) wherein: R1 is chosen from the group consisting of: phenyl group, possibly substituted, —CH2—C6H4—R?1 group, R?1 being chosen from the group consisting of: H, —OH, halogen, alkyl, aryl, CHO, —CN, —NO2, —SR?, —OR?, —NR?R?, —CONR?R?, —COOR?, and —NHCOR?, R? and R? representing independently from each other H, an alkyl group or an aryl group, R?1 being preferably in para position, and —CH2—CO—R? group, R? representing an aryl or heteroaryl group, said aryl and heteroaryl groups being possibly substituted, R2 is chosen from the group consisting of: —OH and halogen, and R3, R4, R5 and R6 are in particular H, for its use for the prevention and/or the treatment of bacterial infections.
    Type: Application
    Filed: April 8, 2011
    Publication date: April 25, 2013
    Inventors: Yap Jean-Bertrand Boum, II, Tamara Basta-Le-Berre, Ursula Liebl, Hannu Myllykallio
  • Publication number: 20130090355
    Abstract: The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.
    Type: Application
    Filed: April 28, 2011
    Publication date: April 11, 2013
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventor: Anne R. Bresnick
  • Publication number: 20130079396
    Abstract: The present invention relates to benzylidene indanones of general formula 1. The compounds exhibited tubulin polymerisation inhibition. A series of compounds 2-benzylidene 3-(3,4,5-trimethoxyphenyl) indanones having general formulae 1 were synthesized from gallic acid through a chemical process. 2-(3,4-Methylenedioxybenzylidine), 3-(3,4,5-trimethoxyphenyl), 4,5,6-trimethoxyindanone (8), a representative compound of this series possessing the molecular formulae C29H28O9, was synthesized from gallic acid and exhibits potent anticancer activity. Compound 8 was evaluated for acute oral activity in Swiss albino mice and found to be safe up to 300 mg/kg body weight. The anticancer activity of the compounds has been determined, in order to obtain new potent and cost effective molecules using an in vitro cytotoxicity assay.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 28, 2013
    Applicant: Council of Scientific and Industrial Research
    Inventor: Council of Scientific and Industrial Research